Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Venclexta Venetoclax Obinutuzumab Obinutuzumab for CLL Reimburse with clinical criteria and/or conditions Complete
Venclexta in combo Rituximab Venetoclax Chronic Lymphocytic Leukemia (CLL) Reimburse with clinical criteria and/or conditions Complete
Verkazia cyclosporine Severe vernal keratoconjunctivitis, pediatric (≥4 years) Reimburse with clinical criteria and/or conditions Complete
Verquvo vericiguat Heart failure Reimburse with clinical criteria and/or conditions Complete
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Reimburse with clinical criteria and/or conditions Complete
Verzenio Abemaciclib Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Reimburse with clinical criteria and/or conditions Active
Vesicare Solifenacin succinate Bladder, overactive Do not list Complete
Vesicare Solifenacin succinate Bladder, overactive List with clinical criteria and/or conditions Complete
VesiFlow Solifenacin succinate / tamsulosin hydrochloride Benign prostatic hyperplasia Withdrawn